Tuesday, 2nd September Melbourne Immunotherapy Spring Symposium 2025

• Next-gen DC1 immunotherapy - Shalin Naik
• Identifying long-lived perinatal regulatory T cells as a target to enhance anti-tumour immunity - Tobias TP Poch
• SCFA producing capabilities of the gut microbiota enhance tumor-specific CD127⁺CD8⁺ T cell immunity against melanoma   - Annabell Bachem
• T cell immunity to metastatic melanoma - Thomas Gebhardt

• The Role of Regulated Cell Death in OSCC Development and in Therapeutic Approaches for Combinative Immunotherapy for Late-Stage Disease - Lorraine O'Reilly
• Targeting Treg cell necroptosis: a potential new mode of immunotherapy - Asma Rahman
• A Novel Targeted Regulatory T Cell Therapy for HLA-DR3-associated Systemic Lupus Erythematosus - Jessica Whui Yuin Wu

• My secret double life - Academic by Day, Biotech Exec by Night - Nicholas Huntington
• TBC - Rebecca Skinner
• Collaboration, Countermeasures and Care: Advancing Health Security from the Region to Globe - Felicia Pradera
• Translation of mRNA technology from bench to clinic. - John Power

5:40PM Open Discussion

• 30-Parameter Flow Cytometry Panels for Immunophenotyping Murine Models of High-Grade Serous Ovarian Cancer - Jasmine Chuah
• An In-depth Immunopeptidomics Analysis of Ewing Sarcoma Cell Lines to Find Therapeutic Targets for HLA-dependent T cell-based Immunotherapy - Grace Huang
• Irradiation modulates the immunopeptidome of paediatric H3K27M Diffuse mid line gliomas - Nurfarhanah Syed Sulaiman
• HLA-bound peptides derived from non-coding RNAs have a high contribution in the Paediatric Diffuse Midline Glioma immunopeptidome. - Tima Shamekhi
• Harnessing early phenotype CD4⁺ CAR-T cells for treatment of solid tumours - Selvi Jegatheeson
• Engineering EphB1-CAR T cell immunotherapy for paediatric high-grade gliomas - Innocent IO Okpako
• Enhancing CAR T-cell Function Via Dual-targeting of 4-1BB and TGF-β - Arthur (Xuan) Wang
•   An iPSC-derived haematopoietic cell model of Wiskott-Aldrich Syndrome reveal novel defects in cell differentiation and function - Katharine J Goodall
• Immune complement C5 inhibition does not alter placental or vascular dysfunction in preeclampsia - Natasha de Alwis
• REGULATION OF PD-L1 AND PD-L2 EXPRESSION IN DENDRITIC CELLS DURING INFLAMMATION AND TUMOUR IMMUNOTHERAPY - Christophe Macri
• Lewis Y antigen as a Novel Target for CAR (Chimeric Antigen Receptor) T-cell therapy in patients with Neuroendocrine prostate cancer. - Weronika Kulakowska
• Unveiling Immunotherapy Targets in Granulosa Cell Tumours Using Mass Spectrometry Based Immunopeptidomics - Terry Lim
• Interrogating anti-tumour immune responses to improve adoptive T cell therapy against metastatic melanoma - Lewis Newland
• Enhanced efficacy of FOXO1-expressing CAR T cells in human prostate cancer patient-derived xenografts - Sophie G Harrison
• Using VIPERs & SNIPRs to engineer safer CAR T cell therapies for glioblastoma - Krishneel Prasad
• Next-generation dendritic cell immunotherapy for intractable solid cancers - Devi Jenika
• Defining the cellular networks that underlie the formation and maturation of murine tumour tertiary lymphoid structures - Raymond Z Qin
• Identifying novel metabolic regulators of CD8+ T cell fate using physiological media - Anni A. Zhang
• Measuring the influence of TOX in peripheral CD8+ T cell tolerance - Christian Deo T. Deguit
• CAR-DC1: A novel next-generation dendritic cell therapy for targeting solid tumours - Shengbo Zhang
• Enhancing chimeric antigen receptor (CAR) T cell therapy for paediatric sarcoma through CAR T engineering and tumour microenvironment rewiring - Enola Roussel
• Identification of Novel Therapeutically Relevant Tumour-Specific Antigens from Non-Classical HLA-F and HLA-G in Diffuse Intrinsic Pontine Glioma (DIPG) - Nivedhitha Selvakumar
• Peripheral Immunity in Poor Graft Function - Arwen Nguyen-Ngo
• T cell modulation by Bruton's tyrosine kinase (BTK) inhibitors: comparing ibrutinib and pirtobrutinib in a preclinical immunology platform - Minh Dinh
• Establishment of a Human Stem Cell Platform to Study Post-Viral Pulmonary Fibrosis - Jack T Murphy
• CFTR mutation alters host response to rhinovirus in iPSC-derived airway cells - Katelyn Patatsos
• Respiratory Group A Strep infections in stem cell models reveals divergent airway and alveolar epithelial cell responses - Jeremy Wiyana
• Identification of T:B cell multimers after bispecific T cell engagement, using both conventional and imaging flow cytometry - Mandy Ludford-Menting
• Melanoma-Associated Antigens are potential targets for Osteosarcoma Immunotherapy - Mersedeh Shayan
• Identification of immunological responses to blinatumomab treatment in B-Acute Lymphoblastic Leukaemia (B-ALL) patients - Joanne E Davis
• Investigating the effects of perioperatively administered therapies on postoperative immune status using spectral flow cytometry and high-dimensional analysis workflows - Yilei (Evelyn) Yang
• Circulating tumour DNA-directed consolidation with epcoritamab alone or in combination with lenalidomide and rituximab is feasible in the early post-CAR-T population at high risk of relapse: preliminary results from EpLCART - Mark R Dowling
• Immunopeptidomic Discovery For Low Input Clinical Samples - Gabriel Goncalves
• Engineering a Flexible Human Alveolar Model from Stem Cells - Tammy Dandeniya
• Investigating leukaemic intrinsic mechanisms of CD19^+/+ B-ALL relapse post-CAR T cell therapy - Evelyn Yang
• TP53 Mutations R175H and R248W Alter the HLA-I Immunopeptidome and Enhance Self-Peptide Presentation in Acute Myeloid Leukemia - Farnaz FF Fahimi
• Multi-dimensional Immunopeptidomic Analysis of Tumour, PBMC, and Plasma in Glioma - Erwin Tanuwidjaya
• A novel CAR-T cell therapy to treat T cell lymphoma - Criselle Dr D'Souza
• CRISPR-Cas13b-mediated silencing of PD-1 as a strategy to reverse immune exhaustion in HIV infection - Jeanette Yang
• Modelling T cell immunotherapy response in colorectal cancer in vitro - Simon Manuel ST Tria
• Beyond PD-1/PD-L1: Exploring a Novel Immune Checkpoint Ligand as a Breast Cancer Therapeutic Target - Sapna Srivastava
• Exploiting a pan-cancer antigen for the development of T cell-based immunotherapies - Roberta Mazzieri
• Chronic inflammation sustains, in the absence of antigen, a potent CD8⁺ effector T cell response leading to overwhelming immunopathology - Sining Li
• Deciphering the tumour microenvironment in chronic lymphocytic leukaemia - Yuxi Cao
• Exploiting highly immunogenic tumour cell lysate to improve the therapeutic efficacy of cancer vaccines for triple-negative breast cancer and glioblastoma - Davide Moi

A surprise toolkit for crazy successful research

Strategy, resilience & drive. Beautiful writing skills … and the ability to get along. Professor Tong will discuss the critical skills to rapidly scale the academic ladder.

Presented by: Professor Stephen Tong (NHMRC-funded clinician and bestselling author of The Birth Book)